305 Ill. Comp. Stat. § 5/5-4.1. Co-payments: Medical Assistance – Illinois
Status: Enacted Year Enacted: 1981
Co-payments are permissible for most health care services, but not for chronic illness treatment. There is a $2 co-pay for generic drugs.
Download
35 Pa. Stat. and Cons. Stat. Ann. §§ 960.1 through 960.7: Generic Equivalent Drug Law – Pennsylvania
Status: Enacted Year Enacted: 1976
It is the purpose of this act to permit consumers to secure necessary drugs at the most economical cost consistent with the professional discretion of the purchaser’s physician and pharmacist.
Download
40 Pa. Stat. and Pa. Cons. Stat. §§ 4501 through 4503, 4531 through 4535, 4551 through 4562: Pharmacy Audit Integrity and Transparency Act – Pennsylvania
Status: Enacted Year Enacted: 2016
Governs PBM cost transparency requirements.
Download
A 00612 (see companion bill S 02391) – New York
Introduced: 2019 Status: Inactive / Dead
Requires the commissioner of health to establish and publish a list of generic drug products.
A 01924 – New York
Introduced: 2019 Status: Inactive / Dead
Authorizes a pharmacist to substitute a brand name prescription drug for the generic equivalent of such drug if requested to do so by the patient and record the request.
A 1396 (see companion bill S 3762) – New York
Introduced: 2021 Status: Enacted
Provides for pharmacy benefit management and the procurement of prescription drugs to be dispensed to patients, or the administration or management of prescription drug benefits; sets forth definitions; provides for funds received by a pharmacy …
A 144 (see companion bill S 4181) – New York
Introduced: 2023 Status: In Process
Requires the commissioner of health to establish and publish a list of generic drug products.
A 1747 (see companion bill S 329) – New Jersey
Introduced: 2022 Status: In Process
This bill establishes the Prescription Drug Affordability Board (Board), which will be charged with protecting New Jersey residents, State and local governments, health benefits plans, health care providers, licensed pharmacies, and other stakeholders within the …
A 1923 (see companion bill S 5158) – New York
Introduced: 2021 Status: In Process
Requires the commissioner of health to establish and publish a list of generic drug products.
A 2240 (see companion bill S 1667) – New Jersey
Introduced: 2022 Status: In Process
Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.
A 236 (see companion bill S 5471) – New York
Introduced: 2017 Status: Inactive / Dead
REQUIRES THE COMMISSIONER OF HEALTH TO ESTABLISH AND PUBLISH A LIST OF GENERIC DRUG PRODUCTS: The commissioner shall establish and publish a list of drug products matched to brand name drugs with which they have …
A 3693 (see companion bill S 1350) – New York
Introduced: 2023 Status: Enacted
Relates to brand-name drugs with and without an AB generic equivalent; amends the effective date from January to July next succeeding the date on which it shall have become a law. Sections 1-3 provide that …
A 3987 (see companion bill S 1590) – New Jersey
Introduced: 2018 Status: Inactive / Dead
PROHIBITS EXCESSIVE INCREASES IN PRICES CHARGED FOR ESSENTIAL OFF-PATIENT AND GENERIC PRESCRIPTION DRUGS AND BIOLOGICAL PRODUCTS: manufacturers and wholesale distributors may not engage in price gouging in the sale of an essential off-patent or generic …
A 5289 – New York
Introduced: 2021 Status: In Process
Authorizes a pharmacist to substitute a brand name prescription drug for the generic equivalent of such drug if requested to do so by the patient and record the request.
A 7196 (see companion bill S 5169) – New York
Introduced: 2019 Status: Inactive / Dead
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
A 7245 (see companion bill S 4370) – New York
Introduced: 2021 Status: In Process
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, is to …